“Second-Line Treatment With Axitinib: An Effective and Well-Tolerated Weapon in the Therapeutic Sequence of Clear Cell Renal Cell Carcinoma”. Working Paper of Public Health 4, no. 1 (June 15, 2015). Accessed May 30, 2026. https://journals.pagepress.net/wpph/article/view/6697.